HR 1520
116th Congress
House
Economics and Public Finance
Appropriations
Congressional oversight
Drug safety, medical device, and laboratory regulation
Executive agency funding and structure
Government information and archives
Licensing and registrations
Further Extension of Continuing Appropriations Act, 2021
Introduced: March 5, 2019
See on congress.gov
Everywhere this bill has been
31 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 22, 2020
Became Public Law No: 116-246.
Dec 22, 2020
Signed by President.
Dec 21, 2020
Presented to President.
Dec 21, 2020
Message on Senate action sent to the House.
Dec 21, 2020
Senate agreed to the House amendment to the Senate amendment to H.R. 1520 by Voice Vote. (consideration: CR S7923)
Dec 21, 2020
Resolving differences -- Senate actions: Senate agreed to the House amendment to the Senate amendment to H.R. 1520 by Voice Vote.
Dec 21, 2020
Message on House action received in Senate and at desk: House amendment to Senate amendment.
Dec 21, 2020
House agreed to the Senate amendment with an amendment pursuant to the provisions of H.Res. 1271. (consideration: CR H7300; text of amendment in the nature of a substitute: CR H7300)
Dec 11, 2020
Message on Senate action sent to the House.
Dec 10, 2020
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7396-7397)
Dec 10, 2020
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S7396-7397)
Dec 10, 2020
Measure laid before Senate by unanimous consent. (consideration: CR S7396-7397)
Dec 10, 2020
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
May 9, 2019
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 8, 2019
Motion to reconsider laid on the table Agreed to without objection.
May 8, 2019
On motion to suspend the rules and pass the bill, as amended Agreed to by recorded vote (2/3 required): 421 - 0 (Roll no. 188). (text: CR H3485-3486)
May 8, 2019
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by recorded vote (2/3 required): 421 - 0 (Roll no. 188).(text: CR H3485-3486)
May 8, 2019
Considered as unfinished business. (consideration: CR H3491-3492)
May 8, 2019
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Ms. Eshoo objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
May 8, 2019
DEBATE - The House proceeded with forty minutes of debate on H.R. 1520.
May 8, 2019
Considered under suspension of the rules. (consideration: CR H3485-3486)
May 8, 2019
Ms. Eshoo moved to suspend the rules and pass the bill, as amended.
May 3, 2019
Placed on the Union Calendar, Calendar No. 26.
May 3, 2019
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-48.
Apr 3, 2019
Ordered to be Reported (Amended) by Voice Vote.
Apr 3, 2019
Committee Consideration and Mark-up Session Held.
Mar 27, 2019
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Mar 27, 2019
Subcommittee Consideration and Mark-up Session Held.
Mar 6, 2019
Referred to the Subcommittee on Health.
Mar 5, 2019
Referred to the House Committee on Energy and Commerce.
Mar 5, 2019
Introduced in House
Votes taken on this bill
1
| Date | Chamber | What was voted on | Result | Yes–No | |
|---|---|---|---|---|---|
| May 8, 2019 | House · vote #188 | On Motion to Suspend the Rules and Pass, as Amended | Passed | 421–0 | See who voted → |
Plain-English summary
Purple Book Continuity Act of 2019
This bill modifies requirements for the Food and Drug Administration to publish information regarding biological products.
What's happening now
Became Public Law No: 116-246.
Committees of jurisdiction
3